The Life Sciences Sector Deal announced by the British government will support healthcare innovation and back businesses to create high-paid, high-quality jobs as part of UK’s industrial strategy.
The deal, backed by wide range of organisations, will bring together 10 companies to support healthcare innovation.
UCB, a multinational biopharmaceutical company headquartered in Brussels (Belgium) is investing around €1,1 billion in research and development, including in a new state-of-the-art facility. The company is focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases in immunology or neurology.
The new programme, backed by up to €88 million of government funding, will study 5 million healthy people to develop new diagnostic tests using AI.
The UK remains the number 1 destination for life sciences inward investment in Europe, ranks number 2 globally behind the USA. All of the top 25 global pharmaceutical companies, and the top 30 global medical technology companies, operate in the UK. The UK also accounts for 12% of total life sciences academic citations and 18% of the most-cited publications – the second highest share above China, Germany and Canada.